Endocrinology of Recurrent Pregnancy Loss

Francisco Arredondo; Luis S. Noble

doi:10.1055/s-2006-931799

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2006; 24(1): 033-039
DOI: 10.1055/s-2006-931799

Endocrinology of Recurrent Pregnancy Loss

Francisco Arredondo¹ , Luis S. Noble²

¹Assistant Professor, Division of Reproductive Endocrinology and Infertility Case Western Reserve University, Cleveland Ohio
²Associate Clinical Professor, Department of Obstetrics and Gynecology, Texas Tech University Medical Center, and Medical Director of Southwest Center for Reproductive Health, El Paso, Texas

Abstract

ABSTRACT

Following implantation, the maintenance of the pregnancy is dependent on a multitude of endocrinological events that will eventually aid in the successful growth and development of the fetus. Although the great majority of pregnant women have no pre-existing endocrine abnormalities, a small number of women can have certain endocrine alterations that could potentially lead to recurrent pregnancy losses. It is estimated that approximately 8 to 12% of all pregnancy losses are the result of endocrine factors. During the preimplantation period, the uterus undergoes important developmental changes stimulated by estrogen, and more importantly, progesterone. Progesterone is essential for the successful implantation and maintenance of pregnancy. Therefore, disorders related to inadequate progesterone secretion by the corpus luteum are likely to affect the outcome of the pregnancy. Luteal phase deficiency, hyperprolactinemia, and polycystic ovarian syndrome are some examples. Several other endocrinological abnormalities such as thyroid disease, hypoparathyroidism, uncontrolled diabetes, and decreased ovarian reserve have been implicated as etiologic factors for recurrent pregnancy loss.

KEYWORDS

Recurrent pregnancy loss - endocrine factors - prolactin - thyroid - luteal phase - ovarian reserve

Full Text

References

REFERENCES

1 Szlachter N, O'Byrne E, Goldsmith L et al.. Myometrial inhibiting activity of relaxin containing extracts of human corpora lutea of pregnancy. Am J Obstet Gynecol. 1980; 136 584-586
2 Bigazzi M, Nardi E. Prolactin and relaxin: antagonism on the spontaneous motility of the uterus. J Clin Endocrinol Metab. 1981; 53 665
3 Csapo A L, Pulkkinen M O, Wiest W G. Effects of lutectomy and progesterone replacement in early pregnant patients. Am J Obstet Gynecol. 1973; 115 759-764
4 Insler V. Corpus luteum defects. Curr Opin Obstet Gynecol. 1992; 4(2) 203-211
5 Tuckerman E, Laird S M, Stewart R, Wells M, Li T C. Markers of endometrial function in women with unexplained recurrent pregnancy loss. Hum Reprod. 2004; 19(1) 196-205
6 Jacobs M H, Balasch J, Gonzalez-Merlo J M. Endometrial cytosolic and nuclear progesterone receptors in the luteal phase defect. J Clin Endocrinol Metab. 1987; 64 472-478
7 Rosenfeld D L, Garcia C R. A comparison of endometrial histology with simultaneous plasma progesterone determinations in infertile women. Fertil Steril. 1976; 27 1256
8 Koninckx P R, Goddeeries P G, Lauweryns J M, de Hertogh R C, Brosens I A. Accuracy of endometrial biopsy dating in relation to the mid-cycle luteinizing hormone peak. Fertil Steril. 1977; 28 443-445
9 Hensleigh P A, Fainstat T. Corpus luteum dysfunction: serum progesterone levels in the diagnosis and assessment of therapy for recurrent and threatened abortion. Fertil Steril. 1979; 32 396
10 Cumming D C, Honore L H, Scott J Z, Williams K P. The late luteal phase in infertile women: comparison of simultaneous endometrial biopsy and progesterone levels. Fertil Steril. 1985; 43(5) 715-719
11 Noyes R W. Uniformity of secretory endometriosis. Obstet Gynecol. 1956; 7 221
12 Coutifaris C, Myers E R, Guzick D S and NICHD National Cooperative Reproductive Medicine Network et al. Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril. 2004; 82(5) 1264-1272
13 Phung Thi Tho, Byrd J R, McDonough P G. Etiologies and subsequent reproductive performance in 100 couples with recurrent abortion. Fertil Steril. 1979; 32 389-395
14 Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage: a meta-analysis of controlled trials. Br J Obstet Gynaecol. 1989; 96 275
15 Mills J L, Simpson J L, Driscoll S et al.. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med. 1988; 319 1617-1621
16 Karamardian L M, Grimes D A. Luteal phase deficiency: effect of treatment on pregnancy rates. Am J Obstet Gynecol. 1992; 167(5) 1391-1398
17 del Pozo E, Wyss H, Tolis G, Alcaniz J, Campana A, Naflolin F. Prolactin and deficient luteal function. Obstet Gynecol. 1979; 53 282-286
18 Roberts C P, Murphy A A. Endocrinopathies associated with recurrent pregnancy loss. Semin Reprod Med. 2000; 18(4) 357-362
19 Byrne J L, Ward K. Genetic factors in recurrent abortion. Clin Obstet Gynecol. 1994; 37(3) 693-704
20 Dorrington J, Gore-Langton R E. Prolactin inhibits oestrogen synthesis in the ovary. Nature. 1981; 290 600
21 Magoffin D A, Erickson G F. Prolactin inhibition of luteinizing hormone-stimulated androgen synthesis in ovarian interstitial cells cultured in defined medium: mechanisms of action. Endocrinology. 1982; 111 2001-2007
22 McNatty K P, Sawers R S. Relationship between the endocrine environment within the graafian follicle and the subsequent secretion of progesterone by human granulosa cells in culture. J Endocrinol. 1975; 66 391-400
23 Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, Minaguchi H. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril. 1998; 70(2) 246-252
24 Goldsmith R E, Sturgis S H, Lerman J, Stanbury J B. The menstrual pattern in thyroid disease. J Clin Endocrinol Metab. 1952; 12(7) 846-855
25 Davis L E, Lucas M J, Hankins G D, Roark M L, Cunningham F G. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol. 1989; 160 63-70
26 Kriplani A, Buckshee K, Bhargava V L, Takkar D, Ammini A C. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol. 1994; 54(3) 159-163
27 Daniels G H. Thyroid disease and pregnancy: a clinical overview. Endocr Pract. 1995; 1 287-301
28 Nakayama T, Yamamoto T, Kanmatsuse K, Kokubun S. Graves' disease associated with anticardiolipin antibody positivity and acquired protein S deficiency. Rheumatol Int. 2003; 23(4) 198-200
29 Anselmo J, Cao D, Karrison T, Weiss R E, Refetoff S. Fetal loss associated with excess thyroid hormone exposure. JAMA. 2004; 292(6) 691-695
30 Wakim A N, Polizotto S L, Buffo M J, Marrero M A, Burholt D R. Thyroid hormones in human follicular fluid and thyroid hormone receptors in human granulosa cells. Fertil Steril. 1993; 59(6) 1187-1190
31 Steinberger E, Nader S, Rodriguez-Rigau L, Ayala C, Smith K. Prolactin response to thyrotropin-releasing hormone in normoprolactinemic patients with ovulatory dysfunction and its use for selection of candidates for bromocriptine therapy. J Endocrinol Invest. 1990; 13(8) 637-642
32 Del Pozo E, Wyss H, Tolis G et al.. Prolactin and deficient luteal function. Obstet Gynecol. 1979; 53 282-286
33 Davis L E, Leveno K J, Cunningham F G. Hypothyroidism complicating pregnancy. Obstet Gynecol. 1988; 72(1) 108-112
34 Casey B M, Dashe J S, Wells C E et al.. Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol. 2005; 105(2) 239-245
35 Stray-Pedersen B, Stray-Pedersen S. Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol. 1984; 148(2) 140-146
36 Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum Reprod. 1994; 9(7) 1328-1332
37 Bohnet H G, Fiedler K, Leidenberger F A. Subclinical hypothyroidism and infertility. Lancet. 1981; 2(8258) 1278
38 Daya S, Ward S, Burrows E. Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatment in patients with recurrent spontaneous abortion. Am J Obstet Gynecol. 1988; 158(2) 225-232
39 Coutifaris C, Myers E R, Guzick D S et al.. NICHD National Cooperative Reproductive Medicine Network. Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril. 2004; 82(5) 1264-1272
40 Kazer R R. Endometrial biopsy should be abandoned as a routine component of the infertility evaluation. Fertil Steril. 2004; 82(5) 1297-1298 (discussion 1300-1302)
41 Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000; 14(5) 839-854
42 Oates-Whitehead R M, Haas D M, Carrier J A. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2003; (4) CD003511
43 Baloch Z, Carayon P, Conte-Devolx B Guidelines Committee, National Academy of Clinical Biochemistry et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003; 13(1) 3-126
44 Weetman A P. Autoimmune thyroid disease. Autoimmunity. 2004; 37(4) 337-340
45 Kutteh W H, Yetman D L, Carr A C, Beck L A, Scott Jr R T. Increased prevalence of antithyroid antibodies identified in women with recurrent pregnancy loss but not in women undergoing assisted reproduction. Fertil Steril. 1999; 71(5) 843-848
46 Rushworth F H, Backos M, Rai R, Chilcott I T, Baxter N, Regan L. Prospective pregnancy outcome in untreated recurrent miscarriers with thyroid autoantibodies. Hum Reprod. 2000; 15(7) 1637-1639
47 Magaro M, Zoli A, Altomonte L et al.. The association of silent thyroiditis with active systemic lupus erythematosus. Clin Exp Rheumatol. 1992; 10(1) 67-70
48 Santoro N. Research on the mechanisms of premature ovarian failure. J Soc Gynecol Investig. 2001; 8(1 suppl) S10-S12
49 Hak A E, Pols H A, Visser T J, Drexhage H A, Hofman A, Witteman J C. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000; 132(4) 270-278
50 Stewart-Akers A M, Krasnow J S, Brekosky J, DeLoia J A. Endometrial leukocytes are altered numerically and functionally in women with implantation defects. Am J Reprod Immunol. 1998; 39(1) 1-11
51 Matalon S T, Blank M, Ornoy A et al.. The association between anti-thyroid antibodies and pregnancy loss. Am J Reprod Immunol. 2001; 45(2) 72-77
52 Christiansen O B, Nybo Andersen A M, Bosch E et al.. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril. 2005; 83(4) 821-839
53 Mills J L, Simpson J L, Driscoll S G et al.. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med. 1988; 319(25) 1617-1623
54 Greene M F, Hare J W, Cloherty J P, Benacerraf B R, Soeldner J S. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology. 1989; 39(3) 225-231
55 Ray J G, O'Brien T E, Chan W S. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001; 94(8) 435-444
56 Kitzmiller J L, Watt N, Driscoll S G. Decidual arteriopathy in hypertension and diabetes in pregnancy: immunofluorescent studies. Am J Obstet Gynecol. 1981; 141(7) 773-779
57 Lea R G, McCracken J E, McIntyre S S et al.. Disturbed development of the preimplantation embryo in the insulin-dependent diabetic BB/E rat. Diabetes. 1996; 45(11) 1463-1470
58 Keim A L, Chi M M, Moley K H. Hyperglycemia-induced apoptotic cell death in the mouse blastocyst is dependent on expression of p53. Mol Reprod Dev. 2001; 60(2) 214-224
59 Moley K H, Chi M M, Mueckler M M. Maternal hyperglycemia alters glucose transport and utilization in mouse preimplantation embryos. Am J Physiol. 1998; 275(1 pt 1) E38-E47
60 Wyse L J, Jones M, Mandel F. Relationship of glycosylated hemoglobin, fetal macrosomia, and birthweight macrosomia. Am J Perinatol. 1994; 11(4) 260-262
61 Temple R, Aldridge V, Greenwood R et al.. Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population based study. BMJ. 2002; 325(7375) 1275-1276
62 Nielsen G L, Sorensen H T, Nielsen P H et al.. Glycosylated hemoglobin as predictor of adverse fetal outcome in type 1 diabetic pregnancies. Acta Diabetol. 1997; 34(3) 217-222
63 Glueck C J, Wang P, Goldenberg N et al.. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002; 17(11) 2858-2864
64 Sagle M, Bishop K, Ridley N et al.. Recurrent early miscarriage and polycystic ovaries. BMJ. 1988; 297(6655) 1027-1028
65 Glueck C J, Wang P, Fontaine R N et al.. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. 1999; 48(12) 1589-1595
66 Glueck C J, Phillips H, Cameron D et al.. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001; 75(1) 46-52
67 Velazquez E M, Mendoza S G, Wang P et al.. Metformin therapy is lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997; 46(4) 454-457
68 Wang J X, Davies M J, Norman R J. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod. 2001; 16(12) 2606-2609
69 Okon M A, Laird S M, Tuckerman E M et al.. Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil Steril. 1998; 69(4) 682-690
70 Tuckerman E M, Okon M A, Li T et al.. Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril. 2000; 74(4) 771-779
71 Regan L, Owen E J, Jacobs H S. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet. 1990; 336(8724) 1141-1144
72 Watson H, Kiddy D S, Hamilton-Fairley D et al.. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod. 1993; 8(6) 829-833
73 Nardo L G, Rai R, Backos M et al.. High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril. 2002; 77(2) 348-352
74 Westergaard L G, Laursen S B, Andersen C Y. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000; 15(5) 1003-1008
75 Clifford K, Rai R, Watson H et al.. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. BMJ. 1996; 312(7045) 1508-1511
76 Craig L B, Ke R W, Kutteh W H. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril. 2002; 78 487-490
77 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1) 19-25
78 Jakubowicz D J, Iuorno M J, Jakubowicz S et al.. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87(2) 524-529
79 Stadtmauer L A, Wong B C, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome-beyond ovulation induction. Hum Reprod. 2002; 17(12) 3016-3026
80 Trout S W, Seifer D B. Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values?. Fertil Steril. 2000; 74(2) 335-337
81 Gurbuz B, Yalti S, Ozden S et al.. High basal estradiol level and FSH/LH ratio in unexplained recurrent pregnancy loss. Arch Gynecol Obstet. 2004; 270(1) 37-39
82 Hofmann G E, Khoury J, Thie J. Recurrent pregnancy loss and diminished ovarian reserve. Fertil Steril. 2000; 74(6) 1192-1195
83 Aging and Infertility in Women .American Society of Reproductive Medicine (ASRM) Practice Committee Report. http://Available at: www.asrm.org/membersonly/practice/ageandfertility.pdf Accessed January 2002

Luis S NobleM.D.

Associate Clinical Professor, Department of Obstetrics and Gynecology, Texas Tech University Medical Center, Medical Director of Southwest Center for Reproductive Health

El Paso, TX 79912

Email: lsprime@elp.rr.com